ALP (Alkaline Phosphatase)

← Back to Lab Reference Library

Category: Liver & Kidney  |  Also known as: Alkaline Phosphatase, Alk Phos  |  Sample: Serum (fasting preferred; food stimulates intestinal ALP release)

1. What This Test Measures

Alkaline phosphatase (ALP) is a hydrolase enzyme that removes phosphate groups from various substrates at alkaline pH. Unlike ALT and AST (which primarily reflect hepatocyte damage), ALP is expressed predominantly in the biliary epithelium, osteoblasts (bone-forming cells), the intestinal brush border, kidney tubular cells, and the placenta during pregnancy. Each tissue produces its own isoform of ALP, though standard laboratory assays measure total ALP without distinguishing between sources.

This tissue distribution makes ALP fundamentally different from the other liver enzymes in its clinical interpretation: ALP is primarily a marker of cholestasis (impaired bile flow) and increased bone turnover, not hepatocellular injury. Understanding which tissue is the source of ALP elevation is the central clinical question when ALP is elevated.

ALP has a physiological variability that ALT and AST do not:

• Adolescents and growing children: ALP is normally 2 to 5 times adult levels due to active osteoblastic bone growth; this is physiological and does not require investigation
• Pregnancy: ALP rises dramatically in the third trimester from placental ALP production; values 3 to 4 times normal are expected and physiological
• Post-meal: a transient ALP rise occurs after meals from intestinal ALP release; fasting is preferred before drawing ALP for clinical assessment

2. Why This Test Matters

• Distinguishes cholestatic from hepatocellular liver disease: this is ALP's most critical clinical role. Biliary obstruction, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and drug-induced cholestasis produce a pattern of markedly elevated ALP with only mildly elevated ALT and AST. Pure hepatocellular disease (NAFLD, viral hepatitis, alcoholic hepatitis) produces elevated ALT and AST with normal or only mildly elevated ALP. Recognizing this distinction directs entirely different investigations.
• Biliary obstruction detection: cholangiocarcinoma, choledocholithiasis (common bile duct stones), and pancreatic head masses all compress the biliary tree, producing ALP elevations that can reach 5 to 10 times normal before ALT rises significantly. ALP is often the first and most dramatically elevated liver enzyme in obstructive jaundice.
• Infiltrative liver disease: sarcoidosis, lymphoma, amyloidosis, and hepatic metastases infiltrate liver parenchyma and compress bile ductules, producing a disproportionate ALP elevation relative to ALT and AST. This "infiltrative pattern" warrants imaging evaluation.
• Bone disease detection: Paget's disease of bone, bone metastases, healing fractures, and metabolic bone disease all produce ALP elevation from osteoblastic activity. The key differentiating point: GGT is normal in bone-source ALP elevation (GGT is not elevated by bone disease), while GGT is elevated in hepatobiliary-source ALP elevation.
• Primary biliary cholangitis (PBC) monitoring: ALP is the primary monitoring marker for PBC treatment response; the target with ursodeoxycholic acid (UDCA) therapy is ALP reduction to below 1.5 times normal.

3. Standard Lab Reference Range

Population	Standard Range	Units
Adults (general)	44 to 147	U/L
Adolescents (growth phase)	Up to 300 to 500 (physiological)	U/L
Pregnancy (third trimester)	Up to 400 to 500 (physiological)	U/L

Reference ranges vary by laboratory and age. Adult ranges typically reflect a mix of biological ALP variability including subclinical bone turnover variability and post-meal intestinal ALP contributions. Always interpret ALP with knowledge of the patient's age, pregnancy status, and fasting state at time of draw.

4. Optimal Functional Medicine Range

ALP Level	Functional Interpretation
Below 60 U/L	Optimal: minimal biliary and bone turnover activity in a non-growing adult
60 to 80 U/L	Low-normal: acceptable; confirm with GGT and clinical context
80 to 120 U/L	Borderline: evaluate with GGT; if GGT elevated, investigate hepatobiliary cause; if GGT normal, consider bone source
120 to 200 U/L	Elevated: significant hepatobiliary or bone pathology; comprehensive evaluation required
Above 200 U/L	Significantly elevated: biliary obstruction, infiltrative liver disease, or significant bone disease; specialist evaluation indicated
Below 40 U/L	Low: evaluate for zinc deficiency, hypothyroidism, or hypophosphatasia

5. Distinguishing Liver from Bone ALP: The GGT Key

6. What Causes Low ALP?

While high ALP receives most clinical attention, low ALP (below 40 to 44 U/L) is a clinically significant finding that functional medicine addresses:

• Zinc deficiency: zinc is an essential cofactor for ALP enzyme function; ALP activity depends directly on adequate zinc; low ALP alongside other zinc deficiency markers (reduced taste and smell, poor wound healing) warrants zinc supplementation
• Hypothyroidism: thyroid hormone stimulates ALP production; severe hypothyroidism suppresses ALP and can cause myopathy with CK elevation
• Pernicious anemia: B12 deficiency reduces ALP; corrects with B12 replacement
• Hypophosphatasia: rare genetic loss-of-function mutation in the ALP gene causing severely low ALP with resulting bone and dental disease; suspect in adults with unexplained dental loss, stress fractures, or bone pain alongside very low ALP (below 20 U/L)
• Celiac disease: malabsorption of zinc and other ALP cofactors; low ALP that improves on gluten-free diet

7. How to Optimize This Marker

8. The Complete Liver Enzyme Panel: Pattern Interpretation

ALP is the key differentiating marker between biliary (cholestatic) and hepatocellular patterns of liver injury:

Pattern	ALT	AST	GGT	ALP	Interpretation
Hepatocellular (NAFLD)	High	Mildly high	Mildly high	Normal	Liver cell injury; ALP normal distinguishes from biliary
Biliary obstruction	Mildly elevated	Mildly elevated	High	Markedly high	ALP and GGT dominate; classic cholestatic pattern
PBC / PSC	Mildly elevated	Mildly elevated	High	Markedly high	Check AMA for PBC; MRCP for PSC; ALP often above 3x ULN
Bone disease	Normal	Normal	Normal	Elevated	GGT normal with elevated ALP confirms bone source
Infiltrative disease	Normal to mild	Normal to mild	Elevated	Markedly high	Sarcoidosis, lymphoma, metastases in liver; imaging required

9. Related Lab Tests

10. When Testing Is Recommended

• Standard annual metabolic panel; ALP is part of the complete liver enzyme pattern alongside ALT, AST, and GGT
• Suspected biliary obstruction: jaundice, right upper quadrant pain, pale stools, dark urine
• Known or suspected PBC or PSC: periodic ALP monitoring assesses disease activity and treatment response
• Suspected bone disease: elevated ALP with normal GGT directs investigation toward skeletal pathology
• Cancer staging and monitoring: ALP is part of bone metastasis surveillance in prostate, breast, and lung cancers
• Low ALP evaluation: unexplained dental problems, stress fractures, bone pain, or muscle weakness alongside very low ALP (below 40 U/L) warrants hypophosphatasia consideration
• Zinc deficiency assessment: low ALP is a sensitive functional marker of zinc deficiency
• Drug monitoring: medications with cholestatic potential require periodic ALP surveillance

11. Clinical Perspective

12. Frequently Asked Questions